PE-related deaths among patients with cancer increased 44.3% between 2011 and 2020, rising by about 2.9% each year during the study period ( P <.001). On average, the age-adjusted mortality rate (AAMR ...

The FDA has granted priority review to the new drug application for zongertinib to treat adults with unresectable or metastatic, HER2-mutant NSCLC who have received prior systemic therapy.

Inpatient immune checkpoint inhibitor treatment produces poor outcomes across cancer types, according to the largest study of its kind.